Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them

L. Haronikova, O. Bonczek, P. Zatloukalova, F. Kokas-Zavadil, M. Kucerikova, PJ. Coates, R. Fahraeus, B. Vojtesek

. 2021 ; 26 (1) : 53. [pub] 20211215

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011689

Grantová podpora
19-18177Y grantová agentura české republiky
CZ.02.1.01/0.0/0.0/16_019/0000868 european regional development fund
MMCI, 00209805 ministerstvo zdravotnictví ceské republiky
1900073 cancerfonden

Since the discovery of the first MDM2 inhibitors, we have gained deeper insights into the cellular roles of MDM2 and p53. In this review, we focus on MDM2 inhibitors that bind to the p53-binding domain of MDM2 and aim to disrupt the binding of MDM2 to p53. We describe the basic mechanism of action of these MDM2 inhibitors, such as nutlin-3a, summarise the determinants of sensitivity to MDM2 inhibition from p53-dependent and p53-independent points of view and discuss the problems with innate and acquired resistance to MDM2 inhibition. Despite progress in MDM2 inhibitor design and ongoing clinical trials, their broad use in cancer treatment is not fulfilling expectations in heterogenous human cancers. We assess the MDM2 inhibitor types in clinical trials and provide an overview of possible sources of resistance to MDM2 inhibition, underlining the need for patient stratification based on these aspects to gain better clinical responses, including the use of combination therapies for personalised medicine.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011689
003      
CZ-PrNML
005      
20250109080552.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s11658-021-00293-6 $2 doi
035    __
$a (PubMed)34911439
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Haronikova, Lucia $u RECAMO, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic. lucia.haronikova@mou.cz
245    10
$a Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them / $c L. Haronikova, O. Bonczek, P. Zatloukalova, F. Kokas-Zavadil, M. Kucerikova, PJ. Coates, R. Fahraeus, B. Vojtesek
520    9_
$a Since the discovery of the first MDM2 inhibitors, we have gained deeper insights into the cellular roles of MDM2 and p53. In this review, we focus on MDM2 inhibitors that bind to the p53-binding domain of MDM2 and aim to disrupt the binding of MDM2 to p53. We describe the basic mechanism of action of these MDM2 inhibitors, such as nutlin-3a, summarise the determinants of sensitivity to MDM2 inhibition from p53-dependent and p53-independent points of view and discuss the problems with innate and acquired resistance to MDM2 inhibition. Despite progress in MDM2 inhibitor design and ongoing clinical trials, their broad use in cancer treatment is not fulfilling expectations in heterogenous human cancers. We assess the MDM2 inhibitor types in clinical trials and provide an overview of possible sources of resistance to MDM2 inhibition, underlining the need for patient stratification based on these aspects to gain better clinical responses, including the use of combination therapies for personalised medicine.
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a klinické zkoušky jako téma $7 D002986
650    _2
$a bakteriální léková rezistence $x účinky léků $x fyziologie $7 D024881
650    _2
$a lidé $7 D006801
650    _2
$a cílená molekulární terapie $x metody $7 D058990
650    _2
$a nádory $x farmakoterapie $7 D009369
650    _2
$a protoonkogenní proteiny c-mdm2 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D051736
650    _2
$a nádorový supresorový protein p53 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Bonczek, Ondřej, $d 1986- $u RECAMO, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic $u Department of Medical Biosciences, Umea University, 901 87, Umea, Vasterbotten, Sweden $7 xx0327493
700    1_
$a Zatloukalova, Pavlina $u RECAMO, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic
700    1_
$a Kokas-Zavadil, Filip $u RECAMO, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic
700    1_
$a Kucerikova, Martina $u RECAMO, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic $u National Centre for Biomolecular Research, Faculty of Science, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
700    1_
$a Coates, Philip J $u RECAMO, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic
700    1_
$a Fahraeus, Robin $u RECAMO, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic $u Department of Medical Biosciences, Umea University, 901 87, Umea, Vasterbotten, Sweden $u Inserm UMRS1131, Institut de Génétique Moléculaire, Université Paris 7, Hôpital St. Louis, 75010, Paris, France
700    1_
$a Vojtesek, Borivoj $u RECAMO, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic. vojtesek@mou.cz $1 https://orcid.org/0000000161943705 $7 xx0001694
773    0_
$w MED00008291 $t Cellular and Molecular Biology Letters $x 1689-1392 $g Roč. 26, č. 1 (2021), s. 53
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34911439 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20250109080547 $b ABA008
999    __
$a ok $b bmc $g 1789336 $s 1162887
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 26 $c 1 $d 53 $e 20211215 $i 1689-1392 $m Cellular and Molecular Biology Letters $n Cell. Mol. Biol. Lett. $x MED00008291
GRA    __
$a 19-18177Y $p grantová agentura české republiky
GRA    __
$a CZ.02.1.01/0.0/0.0/16_019/0000868 $p european regional development fund
GRA    __
$a MMCI, 00209805 $p ministerstvo zdravotnictví ceské republiky
GRA    __
$a 1900073 $p cancerfonden
LZP    __
$a Pubmed-20220425
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace